Clinical Investigation to Assess a New Artificial Urinary Sphincter to Treat Urinary Incontinence in Men

Study Overview
=================
Brief Summary
-----------------
Prospective multicenter study designed to test the feasibility of the UroMems Artificial Urinary Sphincter.

Detailed Description
-----------------
This study is a prospective, open-label, non-randomized, multi-center, single-arm, study with subjects acting as their own control designed to test the feasibility of a new artificial urinary sphincter the UroMems eAUS (investigational name of device called UroActive).

Official Title
-----------------
First-in-human Study to Assess the UrOMems Artificial Urinary sPHincter In the treAtment of Stress Incontinence

Conditions
-----------------
Urinary Incontinence,Stress

Intervention / Treatment
-----------------
* Device: UroMems artificial urinary sphincter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged >18 years old Male patient Cognitively able and willing to sign an informed consent Stable medication regimen (including prescription, over the counter, and supplements) for the past 3 months Able and willing to comply with follow-up investigations, including maintaining consistent medication use and fluid intake through the primary endpoints Has adequate cognitive and manual capabilities to operate the UroMems eAUS System as assessed by the investigator Is an appropriate surgical candidate and has no medical or mental condition that would interfere with study procedures or confound study outcomes as assessed by the investigator Life expectancy ≥ 5 years as assessed by the investigator Affiliated with an appropriate social security system Has failed or is not a candidate for other treatments for urinary incontinence, either surgical or conservative, including slings, Pro-ACT, etc. (excluding other AUS devices) Negative urine culture prior to the procedure Urinary incontinence assessed by investigator with at least ≥ 50 g in 24-hour pad-weight tests Clinically insignificant post-void residual (PVR) urine defined as < 50 ml and/or no greater than 10% of the voided volume Complains of urine leakage on coughing, laughing, and/or moving and/or presence of orthostatic urine leakage by self-report as recorded in baseline bladder diary Exclusion Criteria: Currently enrolled or plans to enroll in another investigational device or clinical drug trial or has completed an investigational study within 3 months Vulnerable patient (patient deprived of their liberty due to a judicial or administrative decision, patient suffering from psychiatry troubles preventing him from giving his consent, patients hospitalized for reason other than the current clinical investigation, patient under 18 years of age, patient under tutelage, patient having withdrawn his consent) Patients whom the investigator determines to be poor candidate for surgical procedures and/or anesthesia due to physical or mental conditions Patient presenting one or several contraindications of the device Any planned procedure requiring urethral catheterization 12 months after implant procedure (include intermittent catheterization) except for diagnostic purposes Known allergy to UroMems eAUS implantable components Known allergy to intravenous iodine Abnormal Prostate Screening Antigen (PSA), according to site's laboratory standards, unless further investigation confirms the absence of primary prostate cancer or local recurrence assessed by investigator. Uncontrolled diabetes mellitus defined as persistent blood sugar level recordings of >12 mmol/l (216 mg/dl) and a glycosylated hemoglobin (HbA1C) of >9% (75 mmol/mol) over the preceding 3 months History of bleeding diathesis or cannot stop usage of an anti-coagulant until the International Normalized Ratio (INR) is below 1.5 or quick value >70 Any genito-urinary malignancies which are not in remission for at least 2 years or considered cured, except prostate cancer Previous AUS implant Currently has another Active Implantable Medical Device (AIMD) implanted Urge incontinence, mixed incontinence (MI) with a predominant urgency component Overflow urinary incontinence Neurogenic bladder dysfunction that is not treatable or controllable by pharmacological or any alternative methods Abnormal or poor bladder compliance defined as being <30 ml/ cm H2O Bladder neck or urethral stricture that may require any long-term instrumental treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: UroMems artificial urinary sphincter<br>Male adults (18+) with urinary incontinence with reduced outlet resistance due to intrinsic sphincter deficiency. Intervention: device (UroMems artificial urinary sphincter) | Device: UroMems artificial urinary sphincter<br>* Implantation of the device<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of explants and revisions at 6 months after device activation | Rate of explants and revisions | 6 months after device activation | 
| Rate of device activation successes | Rate of device activation successes | 5 weeks after device implantation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects with 50% reduction or greater in 24-hour pad weight test | Number of subjects with 50% reduction or greater in 24-hour pad weight test | 90, 185 and 365 days after activation | 
| Number of subjects with 75% reduction or greater in 24-hour pad weight test | Number of subjects with 75% reduction or greater in 24-hour pad weight test | 90, 185 and 365 days after activation | 
| 3-day bladder diary | Bladder diary will be filled in during 3 consecutive days | 90, 185 and 365 days after activation | 
| General quality of life questionnaire | General quality of life questionnaire | 90, 185 and 365 days after activation | 
| Disease specific questionnaire (level of incontinence) | Disease specific questionnaire (level of incontinence) | 90, 185 and 365 days after activation | 
| Disease specific questionnaire (symptoms and quality of life) | Disease specific questionnaire (symptoms and quality of life) | 90, 185 and 365 days after activation | 
| Disease specific questionnaire (sexual activity) | Disease specific questionnaire (sexual activity) | 90, 185 and 365 days after activation | 
| Disease specific questionnaire (quality of life) | Disease specific questionnaire (quality of life) | 90, 185 and 365 days after activation | 
| Disease specific questionnaire (type of incontinence) | Disease specific questionnaire (type of incontinence) | 90, 185 and 365 days after activation | 
| Post void residuals | Post void residuals will be measured to assess the bladder function | Baseline, within 45 days after baseline (device implantation), 14 days after implantation, 5 weeks after implantation (device activation), and 14, 30, 90, 185, 365 and 730 days after activation | 
| Patient satisfaction | Patient satisfaction questionnaire | 5 weeks after device implantation (device activation), and 14, 30, 90, 185, 365 and 730 days after activation | 
| Physician satisfaction questionnaire | Questionnaire to assess the physician satisfaction regarding the procedure and the device | Within 45 days after baseline (device implantation), 5 weeks after implantation (device activation), and 14, 30, 90, 185, 365 and 730 days after activation | 
| Rate of adverse events | All categories: serious/not serious events and device- and procedure-related effects | Baseline, within 45 days after baseline (device implantation), 14 days after implantation, 5 weeks after implantation (device activation), and 14, 30, 90, 185, 365 and 730 days after activation |